All In Biotech

Drug Trial Radar · NCT06037148

Study to Evaluate Safety, Tolerability and Explorative Efficacy of DM-101PX in Birch Pollen Allergic Participants

A Phase I Dose Escalation Trial to Investigate the Safety, Tolerability, and Explorative Efficacy, Following Environmental Allergen Exposure in a Chamber, of DM-101PX in Participants With Birch Pollen Allergy

Last checked: Nov 19, 2026Latest source record: Mar 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

30

Actual

Start

Sep 7, 2023

Primary completion

Mar 6, 2024

Study completion Mar 6, 2024

Sponsor

Lead sponsor
Desentum OyIndustry
Sponsor type
Industry
First posted
Sep 14, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Other
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Randomized, double-blind placebo-controlled phase I trial with the primary aim to investigate safety and tolerability of three ascending dosing schemes of DM-101-PX in birch pollen allergic adults. As an explorative objective, the trial will also investigate the effect of DM-101PX on the allergic symptoms following birch pollen allergen exposure in a chamber. Expanded access to the study treatment is not available.

Conditions

  • Birch Pollen Allergy

Interventions

  • DM-101PXBiological

    subcutaneous injection of DM-101PX

  • Placebo to Match DM-101PXBiological

    Placebo to match DM-101PX administered subcutaneously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Emergent Adverse EventsTime frame: From the first dose to until 14-28 days from the last dose
  2. Adverse Events of Special InterestTime frame: From the first dose to until 14-28 days from the last dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cliantha Research

    Mississauga, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.